3 recruiting, 2 completed, 1 active not recruiting, 1 enrolling by invitation. 9 Phase 1, 4 Phase 2.
Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction HS235, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | Phase 1 / Phase 2 | Recruiting | 35Pharma Inc., a GSK company | 126 | 2026-10-21 | 2026-10-30 |
| Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction HS135, Placebo - Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension | Phase 1 | Terminated | 35Pharma Inc | 4 | 2025-01-23 | 2025-09-04 |
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease Dapagliflozin 10 MG [Farxiga] - Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction | Phase 1 / Phase 2 | Active not recruiting | Northwestern University | 18 | 2024-01-16 | 2026-07-30 |
| Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction AAV1/SERCA2a - Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction | Phase 1 | Recruiting | Sardocor Corp. | 10 | 2023-08-24 | 2023-09-29 |
| Enhancing the Natriuretic Peptide System in HFpEF MANP, Sacubitril/Valsartan, Oral Placebo - Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases | Phase 1 / Phase 2 | Enrolling by invitation | Horng Chen | 60 | 2022-11-04 | 2026-11-16 |
| Single-Ascending Dose Study of JK07 in Subjects With HFpEF JK07, Matching Placebo - Heart Failure With Preserved Ejection Fraction | Phase 1 | Withdrawn | Salubris Biotherapeutics Inc | 2022-10-21 | 2023-05-31 | |
| Novel Approaches for Improving Vascular Function in Veterans With HFpEF L-Citrulline, Placebo for L-Citrulline, BH4 - Heart Failure With Preserved Ejection Fraction, Inflammation | Phase 1 | Recruiting | VA Office of Research and Development | 90 | 2021-05-19 | 2026-11-16 |
| Developing Oral LT3 Therapy for Heart Failure - HFpEF liothyronine, Placebo - Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 28 | 2020-03-08 | 2025-01-08 |
| Physiological Effects of Grape Seed Extract in Diastolic Heart Failure grape seed extract (MegaNatural BP, Polyphenolics, Inc.) - Diastolic Heart Failure, Hypertensive Heart Disease | Phase 1 | Completed | University of Michigan | 15 | 2010-10-01 | 2017-06-06 |
Heart Failure (4) · Heart Failure, Diastolic (2) · Hypertension, Pulmonary (2) · Renal Insufficiency, Chronic (2) · Euthyroid Sick Syndromes (1) · Fibromatosis, Gingival, 2 (1) · Hypertension (1) · Inflammation (1) · Kidney Diseases (1)
Cardiovascular Diseases (7) · Heart Diseases (5) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Vascular Diseases (3) · Chronic Disease (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Hypertension (2) · Lung Diseases (2) · Male Urogenital Diseases (2) · Renal Insufficiency (2) · Respiratory Tract Diseases (2) · Urogenital Diseases (2)
Anthocyanins (1) · Antioxidants (1) · Atorvastatin (1) · Citrulline (1) · Flavonoids (1) · Flavonols (1) · Grape Seed Extract (1) · Polyphenols (1) · Quercetin (1) · Resveratrol (1) · Triiodothyronine (1) · Wine (1) · dapagliflozin (1) · grp protein, Drosophila (1) · sacubitril and valsartan sodium hydrate drug combination (1)
35Pharma Inc (1) · 35Pharma Inc., a GSK company (1) · Horng Chen (1) · Northwestern University (1) · Salubris Biotherapeutics Inc (1) · Sardocor Corp. (1) · University of Michigan (1) · University of Pennsylvania (1) · VA Office of Research and Development (1)
United States (9)
Anne R Cappola, MD,ScM (1) · David W. Wray, PhD (1) · Monique Champagne, M.Sc. (1) · Paul M McKie (1) · Rupal Mehta, MD (1) · Scott L Hummel, MD, MS (1) · Wilson Tang, MD (1)
I01CX002152 (1), K23HL150236 (1), R61HL146390 (1)